The RAZOR (randomized open vs robotic cystectomy) trial: Study design and trial update

Norm D. Smith, Erik P. Castle, Mark L Gonzalgo, Robert S. Svatek, Alon Z. Weizer, Jeffrey S. Montgomery, Raj S. Pruthi, Michael E. Woods, Matthew K. Tollefson, Badrinath R. Konety, Ahmad Shabsigh, Tracey Krupski, Daniel A. Barocas, Atreya Dash, Marcus L. Quek, Adam S. Kibel, Dipen J Parekh

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

The purpose of the RAZOR (randomized open vs robotic cystectomy) study is to compare open radical cystectomy (ORC) vs robot-assisted RC (RARC), pelvic lymph node dissection (PLND) and urinary diversion for oncological outcomes, complications and health-related quality of life (HRQL) measures with a primary endpoint of 2-year progression-free survival (PFS). RAZOR is a multi-institutional, randomized, non-inferior, phase III trial that will enrol at least 320 patients with T1-T4, N0-N1, M0 bladder cancer with ≈160 patients in both the RARC and ORC arms at 15 participating institutions. Data will be collected prospectively at each institution for cancer outcomes, complications of surgery and HRQL measures, and then submitted to trial data management services Cancer Research and Biostatistics (CRAB) for final analyses. To date, 306 patients have been randomized and accrual to the RAZOR trial is expected to conclude in 2014. In this study, we report the RAZOR trial experimental design, objectives, data safety, and monitoring, and accrual update. The RAZOR trial is a landmark study in urological oncology, randomizing T1-T4, N0-N1, M0 patients with bladder cancer to ORC vs RARC, PLND and urinary diversion. RAZOR is a multi-institutional, non-inferiority trial evaluating cancer outcomes, surgical complications and HRQL measures of ORC vs RARC with a primary endpoint of 2-year PFS. Full data from the RAZOR trial are not expected until 2016-2017.

Original languageEnglish
Pages (from-to)198-205
Number of pages8
JournalBJU International
Volume115
Issue number2
DOIs
StatePublished - Jan 1 2014

Fingerprint

Cystectomy
Robotics
Urinary Diversion
Quality of Life
Lymph Node Excision
Urinary Bladder Neoplasms
Disease-Free Survival
Biostatistics
Neoplasms
Research Design
Safety
Research

Keywords

  • bladder cancer
  • clinical trials
  • cystectomy
  • robotics

ASJC Scopus subject areas

  • Urology

Cite this

The RAZOR (randomized open vs robotic cystectomy) trial : Study design and trial update. / Smith, Norm D.; Castle, Erik P.; Gonzalgo, Mark L; Svatek, Robert S.; Weizer, Alon Z.; Montgomery, Jeffrey S.; Pruthi, Raj S.; Woods, Michael E.; Tollefson, Matthew K.; Konety, Badrinath R.; Shabsigh, Ahmad; Krupski, Tracey; Barocas, Daniel A.; Dash, Atreya; Quek, Marcus L.; Kibel, Adam S.; Parekh, Dipen J.

In: BJU International, Vol. 115, No. 2, 01.01.2014, p. 198-205.

Research output: Contribution to journalArticle

Smith, ND, Castle, EP, Gonzalgo, ML, Svatek, RS, Weizer, AZ, Montgomery, JS, Pruthi, RS, Woods, ME, Tollefson, MK, Konety, BR, Shabsigh, A, Krupski, T, Barocas, DA, Dash, A, Quek, ML, Kibel, AS & Parekh, DJ 2014, 'The RAZOR (randomized open vs robotic cystectomy) trial: Study design and trial update', BJU International, vol. 115, no. 2, pp. 198-205. https://doi.org/10.1111/bju.12699
Smith, Norm D. ; Castle, Erik P. ; Gonzalgo, Mark L ; Svatek, Robert S. ; Weizer, Alon Z. ; Montgomery, Jeffrey S. ; Pruthi, Raj S. ; Woods, Michael E. ; Tollefson, Matthew K. ; Konety, Badrinath R. ; Shabsigh, Ahmad ; Krupski, Tracey ; Barocas, Daniel A. ; Dash, Atreya ; Quek, Marcus L. ; Kibel, Adam S. ; Parekh, Dipen J. / The RAZOR (randomized open vs robotic cystectomy) trial : Study design and trial update. In: BJU International. 2014 ; Vol. 115, No. 2. pp. 198-205.
@article{8837efb391054fc187928b033e0f57fa,
title = "The RAZOR (randomized open vs robotic cystectomy) trial: Study design and trial update",
abstract = "The purpose of the RAZOR (randomized open vs robotic cystectomy) study is to compare open radical cystectomy (ORC) vs robot-assisted RC (RARC), pelvic lymph node dissection (PLND) and urinary diversion for oncological outcomes, complications and health-related quality of life (HRQL) measures with a primary endpoint of 2-year progression-free survival (PFS). RAZOR is a multi-institutional, randomized, non-inferior, phase III trial that will enrol at least 320 patients with T1-T4, N0-N1, M0 bladder cancer with ≈160 patients in both the RARC and ORC arms at 15 participating institutions. Data will be collected prospectively at each institution for cancer outcomes, complications of surgery and HRQL measures, and then submitted to trial data management services Cancer Research and Biostatistics (CRAB) for final analyses. To date, 306 patients have been randomized and accrual to the RAZOR trial is expected to conclude in 2014. In this study, we report the RAZOR trial experimental design, objectives, data safety, and monitoring, and accrual update. The RAZOR trial is a landmark study in urological oncology, randomizing T1-T4, N0-N1, M0 patients with bladder cancer to ORC vs RARC, PLND and urinary diversion. RAZOR is a multi-institutional, non-inferiority trial evaluating cancer outcomes, surgical complications and HRQL measures of ORC vs RARC with a primary endpoint of 2-year PFS. Full data from the RAZOR trial are not expected until 2016-2017.",
keywords = "bladder cancer, clinical trials, cystectomy, robotics",
author = "Smith, {Norm D.} and Castle, {Erik P.} and Gonzalgo, {Mark L} and Svatek, {Robert S.} and Weizer, {Alon Z.} and Montgomery, {Jeffrey S.} and Pruthi, {Raj S.} and Woods, {Michael E.} and Tollefson, {Matthew K.} and Konety, {Badrinath R.} and Ahmad Shabsigh and Tracey Krupski and Barocas, {Daniel A.} and Atreya Dash and Quek, {Marcus L.} and Kibel, {Adam S.} and Parekh, {Dipen J}",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/bju.12699",
language = "English",
volume = "115",
pages = "198--205",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - The RAZOR (randomized open vs robotic cystectomy) trial

T2 - Study design and trial update

AU - Smith, Norm D.

AU - Castle, Erik P.

AU - Gonzalgo, Mark L

AU - Svatek, Robert S.

AU - Weizer, Alon Z.

AU - Montgomery, Jeffrey S.

AU - Pruthi, Raj S.

AU - Woods, Michael E.

AU - Tollefson, Matthew K.

AU - Konety, Badrinath R.

AU - Shabsigh, Ahmad

AU - Krupski, Tracey

AU - Barocas, Daniel A.

AU - Dash, Atreya

AU - Quek, Marcus L.

AU - Kibel, Adam S.

AU - Parekh, Dipen J

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The purpose of the RAZOR (randomized open vs robotic cystectomy) study is to compare open radical cystectomy (ORC) vs robot-assisted RC (RARC), pelvic lymph node dissection (PLND) and urinary diversion for oncological outcomes, complications and health-related quality of life (HRQL) measures with a primary endpoint of 2-year progression-free survival (PFS). RAZOR is a multi-institutional, randomized, non-inferior, phase III trial that will enrol at least 320 patients with T1-T4, N0-N1, M0 bladder cancer with ≈160 patients in both the RARC and ORC arms at 15 participating institutions. Data will be collected prospectively at each institution for cancer outcomes, complications of surgery and HRQL measures, and then submitted to trial data management services Cancer Research and Biostatistics (CRAB) for final analyses. To date, 306 patients have been randomized and accrual to the RAZOR trial is expected to conclude in 2014. In this study, we report the RAZOR trial experimental design, objectives, data safety, and monitoring, and accrual update. The RAZOR trial is a landmark study in urological oncology, randomizing T1-T4, N0-N1, M0 patients with bladder cancer to ORC vs RARC, PLND and urinary diversion. RAZOR is a multi-institutional, non-inferiority trial evaluating cancer outcomes, surgical complications and HRQL measures of ORC vs RARC with a primary endpoint of 2-year PFS. Full data from the RAZOR trial are not expected until 2016-2017.

AB - The purpose of the RAZOR (randomized open vs robotic cystectomy) study is to compare open radical cystectomy (ORC) vs robot-assisted RC (RARC), pelvic lymph node dissection (PLND) and urinary diversion for oncological outcomes, complications and health-related quality of life (HRQL) measures with a primary endpoint of 2-year progression-free survival (PFS). RAZOR is a multi-institutional, randomized, non-inferior, phase III trial that will enrol at least 320 patients with T1-T4, N0-N1, M0 bladder cancer with ≈160 patients in both the RARC and ORC arms at 15 participating institutions. Data will be collected prospectively at each institution for cancer outcomes, complications of surgery and HRQL measures, and then submitted to trial data management services Cancer Research and Biostatistics (CRAB) for final analyses. To date, 306 patients have been randomized and accrual to the RAZOR trial is expected to conclude in 2014. In this study, we report the RAZOR trial experimental design, objectives, data safety, and monitoring, and accrual update. The RAZOR trial is a landmark study in urological oncology, randomizing T1-T4, N0-N1, M0 patients with bladder cancer to ORC vs RARC, PLND and urinary diversion. RAZOR is a multi-institutional, non-inferiority trial evaluating cancer outcomes, surgical complications and HRQL measures of ORC vs RARC with a primary endpoint of 2-year PFS. Full data from the RAZOR trial are not expected until 2016-2017.

KW - bladder cancer

KW - clinical trials

KW - cystectomy

KW - robotics

UR - http://www.scopus.com/inward/record.url?scp=84921461503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921461503&partnerID=8YFLogxK

U2 - 10.1111/bju.12699

DO - 10.1111/bju.12699

M3 - Article

C2 - 25626182

AN - SCOPUS:84921461503

VL - 115

SP - 198

EP - 205

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 2

ER -